Update from Lexeo Therapeutics
In a press release today, July 7, 2025, Lexeo Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LX2006 based on clinical evidence generated on both cardiac and neurologic measures of Friedreich ataxia (FA).
The FDA developed Breakthrough Therapy designation to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).
To learn more, read the full press release and community statement below.
